389 related articles for article (PubMed ID: 24300740)
1. New treatment targets for the management of irritable bowel syndrome.
Rao S; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
[TBL] [Abstract][Full Text] [Related]
2. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
Rothstein RD; Friedenberg FK
Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
[TBL] [Abstract][Full Text] [Related]
5. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
7. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
Vazquez-Roque MI; Bouras EP
Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
[TBL] [Abstract][Full Text] [Related]
8. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
Lacy BE; Chey WD
Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
[TBL] [Abstract][Full Text] [Related]
9. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Saad R; Chey WD
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
[TBL] [Abstract][Full Text] [Related]
10. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Vazquez Roque M; Camilleri M
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies for constipation.
Thayalasekeran S; Ali H; Tsai HH
World J Gastroenterol; 2013 Dec; 19(45):8247-51. PubMed ID: 24363515
[TBL] [Abstract][Full Text] [Related]
12. Lubiprostone for constipation and irritable bowel syndrome with constipation.
Tuteja AK; Rao SS
Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
14. Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad RJ
Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
Ginzburg R; Ambizas EM
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1091-7. PubMed ID: 18680443
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
Lee N; Wald A
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
[TBL] [Abstract][Full Text] [Related]
18. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
[TBL] [Abstract][Full Text] [Related]
19. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
Raschi E; De Ponti F
Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):293-305. PubMed ID: 24387275
[TBL] [Abstract][Full Text] [Related]
20. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
